228410-90-0

Basic information

• Product Name: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE
• Synonyms: 5-BROMO-2-HYDROXY-4-METHYL-3-NITROPYRIDINE;5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE;5-BROMO-4-METHYL-3-NITRO-2(1H)-PYRIDINONE;5-BROMO-4-METHYL-3-NITROPYRIDIN-2-OL;2-Hydroxy-3-Nitro-5-Bromo-4-Picoline;5-Bromo-2-hydroxy-4-methyl-3-nitropyridine 98%;5-Bromo-4-methyl-3-nitro-2-hydroxypyridine;5-BroMo-4-Methyl-3-nitropyridin-2(1H)-one
• CAS NO: 228410-90-0
• Molecular Formula: C₆H₅BrN₂O₃
• Molecular Weight: 233.02
• Product Categories: blocks;Bromides;Pyridines;Pyridine;API intermediates;Pyridine Series
• Mol File: 228410-90-0.mol

Chemical Properties

• Melting Point: 240-243
• Boiling Point: 298.2 °C at 760 mmHg
• Flash Point: 134.1 °C
• Appearance: /
• Density: 1.84 g/cm³
• Vapor Pressure: 0.00129mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: Keep Cold
• PKA: 6.34±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE(228410-90-0)
• EPA Substance Registry System: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE(228410-90-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 228410-90-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE is used as a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE serves as a building block for the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Dye Production:
5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE is used as a precursor in the production of dyes, thanks to its chemical properties that can be manipulated to create a variety of colorants for different applications.
Used in Organic Chemical Synthesis:
5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE is utilized in the synthesis of other organic chemicals, expanding its applications in various chemical processes and industries.
Used in Biological and Medicinal Research:
5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE has been studied for its potential biological and medicinal properties, including anti-cancer and anti-inflammatory effects. Its unique structure makes it a promising candidate for further research and development in therapeutic applications.

InChI:InChI=1/C6H5BrN2O3/c1-3-4(7)2-8-6(10)5(3)9(11)12/h2H,1H3,(H,8,10)

Upstream product

• 21901-18-8 2-hydroxy-4-methyl-3-nitropyridine 
• 5327-32-2 2-acetylamino-4-methylpyridine 
• 142404-82-8 N-(5-bromo-4-methylpyridin-2-yl)acetamide 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 67-56-1 methanol 
• 100367-40-6 2-amino-3-nitro-4-methyl-5-bromopyridine 
• 695-34-1 2-Amino-4-methylpyridine 
• 21901-18-8 4-Methyl-3-nitro-2-pyridone 
• 6635-86-5 2-amino-4-methyl-3-nitropyridine 

Downstream Products

• 1430096-94-8 C₃₂H₄₁N₇O₉ 
• 1430096-96-0 C₅₄H₇₀N₈O₁₆ 
• 1445993-87-2 4-bromo-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1361481-63-1 4-bromo-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1622302-83-3 4-(tert-butyl)-N-(2-methyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1622303-43-8 4-(tert-butyl)-N-(2-methyl-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1622303-44-9 4-(tert-butyl)-N-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1622303-45-0 4-(tert-butyl)-N-(2-(hydroxymethyl)-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1445993-96-3 ethyl 4-bromo-6-methyl-7-oxo-1-toluenesulfonyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate 
• 1446237-40-6 5-bromo-1,4-dimethyl-3-nitro-1,2-dihydropyridin-2-one 

Relevant articles and documents

Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor

We previously reported the 2-oxopyridine-3-carboxamide derivative EC21a as the first small synthetic CB2R positive allosteric modulator which displayed antinociceptive activity in vivo in an experimental mouse model of neuropathic pain. Herein, we extended the structure-activity relationships of EC21a through structural modifications regarding the p-fluoro benzyl moiety at position 1 and the amide group in position 3 of the central core. The characterization in vitro was assessed through radioligand binding experiments and functional assays (GTPγS, cAMP, βarrestin2). Among the new compounds, the derivatives A1 (SV-10a) and A5 (SB-13a) characterized respectively by fluorine atom or by chlorine atom in ortho position of the benzylic group at position 1 and by a cycloheptane-carboxamide at position 3 of the central core, showed positive allosteric behavior on CB2R. They enhanced the efficacy of CP55,940 in [35S]GTPγS assay, and modulated CP55,940-dependent βarrestin2 recruitment and cAMP inhibition. The obtained results extend our knowledge of the structural requirements for interaction with the allosteric site of CB2R.

QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR

The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Compound with BRD4 inhibitory activity, preparation method and application thereof

The invention discloses a compound with BRD4 inhibitory activity, a preparation method and application thereof. The structure of the compound with the BRD4 inhibitory activity is shown as a formula I, and definitions of substituent groups are shown in the specification and claims. The compound provided by the invention has very high bromodomain protein inhibition activity, especially BRD4 targeted inhibition activity, and can be used for treating or/and preventing related diseases mediated by bromodomain protein.

Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies

The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ～7% overall yield.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Chemically programmed antibodies as HIV-1 attachment Inhibitors

Herein, we describe the design and application of two small-molecule anti-HIV compounds for the creation of chemically programmed antibodies. N-Acyl-β-lactam derivatives of two previously described molecules BMS-378806 and BMS-488043 that inhibit the interaction between HIV-1 gp120 and T-cells were synthesized and used to program the binding activity of aldolase antibody 38C2. Discovery of a successful linkage site to BMS-488043 allowed for the synthesis of chemically programmed antibodies with affinity for HIV-1 gp120 and potent HIV-1 neutralization activity. Derivation of a successful conjugation strategy for this family of HIV-1 entry inhibitors enables its application in chemically programmed antibodies and vaccines and may facilitate the development of novel bispecific antibodies and topical microbicides.